Videos

Dr. Abou-Alfa on Emerging PD-L1 Agents in Liver Cancer

May 4th 2016

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering, discusses what is on the horizon for the use of PD-L1 agents in liver cancer.

mNSCLC with Mark Kris, MD and Mark Socinski, MD: Case 1

April 27th 2016

mNSCLC with Mark Kris, MD and Mark Socinski, MD

Mark Socinski, MD: Maintenance Strategies

April 27th 2016

Mark Socinski, MD: Antiangiogenic Therapy in NSCLC

April 27th 2016

Mark Socinski, MD: Evaluating Therapeutic Options

April 27th 2016

Mark Socinski, MD: Lacking Actionable Mutations in NSCLC

April 27th 2016

Mark Kris, MD: Maintenance Strategies

April 27th 2016

Mark Kris, MD: Antiangiogenic Therapy in NSCLC

April 27th 2016

Mark Kris, MD: Evaluating Therapeutic Options

April 27th 2016

Mark Kris, MD: Choosing a Treatment in NSCLC

April 27th 2016

Mark Kris, MD: Lacking Actionable Mutations in NSCLC

April 27th 2016

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD: Case 2

April 27th 2016

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD

Tanios Bekaii-Saab, MD; Chemotherapy as a Possible Option

April 27th 2016

Tara Seery, MD; Chemotherapy as a Possible Option

April 27th 2016

Tanios Bekaii-Saab, MD: KRAS Status in mCRC

April 27th 2016

Tara Seery, MD: KRAS Status in mCRC

April 27th 2016

Tanios Bekaii-Saab, MD: Impact of Third-Line Therapy

April 27th 2016

Tara Seery, MD: Impact of Third-Line Therapy

April 27th 2016

Tanios Bekaii-Saab, MD: Clinical Data Supporting Trifluradine-Tipiracil

April 27th 2016

Tara Seery, MD: Clinical Data Supporting Trifluradine-Tipiracil

April 27th 2016

Tanios Bekaii-Saab, MD: Fourth-Line Therapy in mCRC

April 27th 2016

Tara Seery, MD: Fourth-Line Therapy in mCRC

April 27th 2016

Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab

April 26th 2016

Charles Fuchs, MD: Strategies to Increase RAS Testing

April 26th 2016

Charles Fuchs, MD: Impeding RAS Mutation Testing

April 26th 2016

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

April 26th 2016

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

April 26th 2016

Charles Fuchs, MD: Clinical Importance of RAS Mutations

April 26th 2016

Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

April 26th 2016

Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

April 26th 2016

Videos

Dr. Abou-Alfa on Emerging PD-L1 Agents in Liver Cancer

mNSCLC with Mark Kris, MD and Mark Socinski, MD: Case 1

Mark Socinski, MD: Maintenance Strategies

Mark Socinski, MD: Antiangiogenic Therapy in NSCLC

Mark Socinski, MD: Evaluating Therapeutic Options

Mark Socinski, MD: Lacking Actionable Mutations in NSCLC

Mark Kris, MD: Maintenance Strategies

Mark Kris, MD: Antiangiogenic Therapy in NSCLC

Mark Kris, MD: Evaluating Therapeutic Options

Mark Kris, MD: Choosing a Treatment in NSCLC

Mark Kris, MD: Lacking Actionable Mutations in NSCLC

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD: Case 2

Tanios Bekaii-Saab, MD; Chemotherapy as a Possible Option

Tara Seery, MD; Chemotherapy as a Possible Option

Tanios Bekaii-Saab, MD: KRAS Status in mCRC

Tara Seery, MD: KRAS Status in mCRC

Tanios Bekaii-Saab, MD: Impact of Third-Line Therapy

Tara Seery, MD: Impact of Third-Line Therapy

Tanios Bekaii-Saab, MD: Clinical Data Supporting Trifluradine-Tipiracil

Tara Seery, MD: Clinical Data Supporting Trifluradine-Tipiracil

Tanios Bekaii-Saab, MD: Fourth-Line Therapy in mCRC

Tara Seery, MD: Fourth-Line Therapy in mCRC

Charles Fuchs, MD: Cost Issues With CT Regimens and Bevacizumab

Charles Fuchs, MD: Strategies to Increase RAS Testing

Charles Fuchs, MD: Impeding RAS Mutation Testing

Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Charles Fuchs, MD: RAS Mutations and the Sequence of Therapies

Charles Fuchs, MD: Clinical Importance of RAS Mutations

Charles Fuchs, MD: RAS Mutations in Metastatic Colorectal Cancer

Tanios Bekaii-Saab, MD: Cost Issues With CT Regimens and Bevacizumab

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Phase 3 Data Highlight Orca-T’s Clinical Benefits in Heme Malignancies

Targeting HER2-Low Breast Cancer: the ARX788 Phase 2 Clinical Trial

Response Rates with Pumitamig Plus Chemo Suggest Synergistic Effect

ctDNA Refines Risk in Neoadjuvant-Resistant Breast Cancer

High Survival Seen with Nogapendekin Alfa Inbakicept in Papillary NMIBC